Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics

被引：16
|
作者：
Feldman, Steven R. [1 ]
Pelletier, Corey L. [2 ]
Wilson, Kathleen L. [3 ]
Mehta, Rina K. [2 ]
Brouillette, Matthew A. [3 ]
Smith, David [3 ]
Bonafede, Machaon M. [3 ]
机构：
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Dermatol, Winston Salem, NC 27103 USA
[2] Celgene Corp, Summit, NJ USA
[3] IBM Watson Hlth, Cambridge, MA 02142 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2019年 / 8卷 / 01期
关键词：
adherence; apremilast; healthcare costs; persistence; psoriasis;
D O I：
10.2217/cer-2018-0097
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: Biologics and apremilast have advanced psoriasis management by adding treatment options. This study evaluated persistence, adherence and healthcare costs among biologic-naive patients receiving apremilast or biologics. Methods: Administrative claims data for adults starting apremilast or biologics from 1 January 2013 to 30 June 2016 were matched based on demographics. Results: Apremilast (n=703) and biologics (n=1378) had similar baseline characteristics. 12-month persistence and adherence rates were similar. Adjusted total healthcare costs were lower with apremilast versus biologics (p<0.001) due to lower total outpatient pharmacy costs (p<0.001). Conclusion: Real-world apremilast users had similar adherence and lower total healthcare costs versus biologic users. Apremilast's cost advantage was evident regardless of whether the patients were persistent or nonpersistent, or switched or did not switch treatments.
引用
收藏
页码：45 / 54
页数：10
相关论文
共 50 条
  • [21] Real-world treatment patterns of adults with psoriasis initiated on apremilast or biologics
    Wu, Jashin J.
    Wang, Ann
    Jobson, Greeta
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB101 - AB101
  • [22] Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients
    van Lumig, P. P. M.
    van de Kerkhof, P. C. M.
    Boezeman, J. B. M.
    Driessen, R. J. B.
    de Jong, E. M. G. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (05) : 593 - 600
  • [23] COMPARISON OF PERSISTENCE AND ADHERENCE IN BIOLOGIC NAIVE PATIENTS WITH PSORIATIC ARTHRITIS INITIATING APREMILAST OR BIOLOGICS IN A US ADMINISTRATIVE CLAIMS DATABASE
    Feldman, S. R.
    Bonafede, M. M.
    Pelletier, C.
    Mehta, R.
    Brouillette, M.
    Smith, D.
    Wilson, K. L.
    Ni, Q.
    VALUE IN HEALTH, 2017, 20 (09) : A541 - A541
  • [24] Real-World Switch Rates of Biologics and Associated Costs in Patients With Psoriasis
    Wu, Jashin J.
    Patel, Manish
    Li, Chao
    Garg, Vishvas
    Mandava, Monika Rao
    Armstrong, April W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB81 - AB81
  • [25] Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis
    Kaplan, David L.
    Ung, Brian L.
    Pelletier, Corey
    Udeze, Chuka
    Khilfeh, Ibrahim
    Tian, Marc
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 369 - 377
  • [26] EARLY USE OF VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS: A REAL-WORLD ANALYSIS OF HEALTHCARE UTILIZATION
    Patel, Haridarshan
    Khalid, Javaria M.
    Shah, Surbhi
    Shah, Rikisha
    Berger, Ariel
    GASTROENTEROLOGY, 2018, 154 (06) : S371 - S371
  • [27] Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis
    Wu, Jashin J.
    Wang, Ching An
    Jobson, Greeta
    Davidson, David
    Kalirai, Samaneh
    Zhu, Julia
    Suryavanshi, Manasi
    Mittal, Mayank
    Patel, Vardhaman
    Seigel, Lauren
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [28] Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced
    Megna, Matteo
    Ruggiero, Angelo
    Torta, Ginevra
    Martora, Fabrizio
    Bianco, Mariateresa
    Potestio, Luca
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (10) : 1186 - 1189
  • [29] Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies
    Thai, Sydney
    Zhuo, Joe
    Zhong, Yichen
    Xia, Qian
    Chen, Xiu
    Bao, Ying
    Dhanda, Devender
    Priya, Lawshia
    Wu, Jashin J. J.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [30] Quality of life and pruritus over 52 weeks of apremilast treatment in biologic-naive patients with moderate plaque psoriasis: Results of a real-world, multicenter, prospective study in Greece (APRAISAL)
    Ioannides, Dimitrios
    Tampouratzi, Eleftheria
    Rigopoulos, Dimitrios
    Drosos, Alexandros
    Rovithi, Evangelia
    Papadavid, Evangelia
    Papageorgiou, Marina
    Bassukas, Ioannis
    Zafiriou, Efterpi
    Panagakis, Pantelis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB150 - AB150
12345